Abstract:1109 Objectives: As one of the most studied N-Methyl-D-aspartate receptor (NMDAR) subunits, GluN2B is an important therapeutic target of drug discovery for the treatment of schizophrenia, stroke, and neuro-pain.[1] The in vivo quantification of GluN2B subunit by PET imaging could help to elucidate its pathophysiological roles in these diseases and further facilitate target engagement studies. However, there is no PET ligand for human use, which represents an urgent and unmet clinical need. Herein, an 18F-labeled compound 2-((1-(4-[18F]fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine ([18F]1, Figure 1) was successfully prepared as a new GluN2B-selective PET ligand for NMDAR imaging. Compound 1 has high affinity and selectivity toward GluN2B subunit and optimal logD value of 2.89. Preclinical evaluation of [18F]1 including in vitro autoradiography (ARG) studies was carried out to determine its binding specificity.\n Methods: Compound 1 (Figure 1A) displayed desirable binding potency to GluN2B subunit with IC50 value of 28 nM. With [18F]1 in hand, the in vitro ARG were conducted in brain sections of both rat and non-human primate (NHP) with the incubation of [18F]1 (37 kBq/mL, 1.58 nM) in tri-HCl buffer (50 mM, pH = 7.4) for 60 min. The blocking experiments were carried out by preincubation (30 min) using the solutions (10 μM, 0.1% DMSO, 1% ethanol in Tris-HCl buffer) of cold compound 1 and a GluN2B-selective negative allosteric modulator (NAM) BMT-108908[2]. Ex vivo biodistribution was performed after intravenous injection of [18F]1 (740 kBq/100 μL in saline containing 5% ethanol) to mice through tail vein, and the mice were sacrificed at different time points of 2, 10, 30, and 60 min. The uptakes in tissues/organs of interest were expressed as % ID/g.\n Results: As shown in Figure 1 (B, C, and D), the radioactivity of [18F]1 was distributed with high density in rat brain regions of hippocampus, frontal cortex, and striatum, intermediate in Thalamus, but no significant signals in the cerebellum, which is in accordance with the expression of GluN2B subunit in the brain of rodent.[3] In addition, the specific binding of [18F]1 in these brain regions was strongly blocked by both compound 1 and BMT-108908, which confirmed its selectivity and specificity to GluN2B subunit. Furthermore, in NHP brain sections (Figure 1E), the radioactivity was observed highest in brain regions of hippocampus, entorhinal cortex, and insular cortex, moderate in caudate nucleus and putamen, low in the thalamus and claustrum, and no significant binding in white matter of forebrain. The special distribution of the signals was preciously blocked by both compound 1 (Figure 1F) and BMT-108908 (Figure 1G). In addition, the ex vivo biodistribution in mice revealed that [18F]1 could readily penetrate blood-brain barrier (BBB) with a good initial brain uptake of 3.60% ID/g (brain2min) and a rapid brain washout rate (brain60min = 0.018% ID/g), which is beneficial to brain PET imaging.\n Conclusions: [18F]1 showed high selective and specific binding to GluN2B subunit in in vitro ARG with brain sections of both rat and NHP, which could be preciously blocked by compound 1 itself and BMT-108908. Furthermore, [18F]1 possessed good capability of BBB penetration and fast washout rate from the mice brain. These results suggested that [18F]1 had great potential utility in PET imaging of GluN2B subunit.\nAcknowledgments: We thank Drs. Thomas Brady (Nuclear Medicine, MGH) for his helpful discussion.\n References: 1. Mony L et al. Br. J. Pharmacol. 2009;157:1301-1317.2. Marcin LR et al. ACS Med. Chem. Lett. 2018;9:472-477.3. Monyer H et al.. Neuron. 1994;12:529-540.

Visualization of AMPA receptors in living human brain with positron emission tomography

Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography

A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors

Synthesis, pharmacology and preclinical evaluation of 11C-labeled 1,3-dihydro-2H-benzo[d]imidazole-2-ones for imaging γ8-dependent transmembrane AMPA receptor regulatory protein

Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), Α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors

Evaluation of thiadiazine-based PET radioligands for imaging the AMPA receptor

Synthesis and preliminary studies of 11 C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2.

Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators

Preclinical evaluation of a new 18F-labled probe as a potent PET imaging ligand for GluN2B subunit in NMDA receptors

Preclinical Evaluation of Azabenzimidazole‐Based PET Radioligands for γ‐8 Dependent Transmembrane AMPA Receptor Regulatory Protein Imaging

Preclinical Evaluation Of Radiolabeled Negative Allosteric Modulators For Pet Imaging Of Metabotropic Glutamate Receptor 2

AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer

[18F]-GE-179 positron emission tomography (PET) tracer for N-methyl-d-aspartate receptors: One-pot synthesis and preliminary micro-PET study in a rat model of MCAO.

NMDA receptor ion channel activation detected in vivo with [18F]GE-179 PET after electrical stimulation of rat hippocampus

Synthesis and evaluation of 1-(cyclopropylmethyl)-4-(4-[11C]methoxyphenyl)-piperidin-1-yl-2-oxo-1,2-dihydropyridine-3-carbonitrile ([11C]CMDC) for PET imaging of metabotropic glutamate receptor 2 in the rat brain.

Synthesis of K+ channel radioligand [18F]5-methyl-3-fluoro-4-aminopyridine and PET imaging in mice

Synthesis of K+ channel radioligand [ F]5-methyl-3-fluoro-4-aminopyridine and PET imaging in mice

Improved Radiosynthesis and Automation of [11C]2‐(2,6‐Difluoro‐4‐((2‐(N‐methylphenylsulfonamido)ethyl)thio)phenoxy)acetamide ([11C]K2) for Positron Emission Tomography of the Glutamate α‐Amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole Propionic Acid (AMPA) Receptor

Synthesis and preclinical evaluation of <SUP>11</SUP>C-labeled (6-aryl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)acetamide for imaging GluN2B subunit of NMDA receptors